Categories
GeekWire

A-Alpha Bio raises $2.8M for drug discovery

A-Alpha Bio team
The A-Alpha Bio team includes scientist Emily Engelhart, principal scientist David Colby, co-founder and CEO David Younger, co-founder and chief technology officer Randolph Lopez and engineering associate Charles Lin. (A-Alpha Bio Photo)

A Seattle startup that took root at the University of Washington has closed a $2.8 million seed round for a drug discovery platform that can sort through millions of protein interactions at once.

“We expect that we can go considerably further than that,” said David Younger, the co-founder and CEO of A-Alpha Bio.

A-Alpha Bio’s genetically engineered protein analysis technology, known as AlphaSeq, has the potential to speed up the process of evaluating drug candidates. That’s what attracted interest from investors including OS Fund, which led the seed round, plus AME Cloud Ventures, Boom Capital, Madrona Venture Group, Sahsen Ventures, Washington Research Foundation and a number of angel investors.

Get the full story on GeekWire.

By Alan Boyle

Mastermind of Cosmic Log, contributing editor at GeekWire, author of "The Case for Pluto: How a Little Planet Made a Big Difference," president of the Council for the Advancement of Science Writing. Check out "About Alan Boyle" for more fun facts.

Leave a Reply